We use cookies for a better user experience. Read our Privacy Policy

I Agree

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market (Product: Buphenyl, Ravicti, Ammonul, Dietary Supplements, and Others; Route of Administration: Oral and Intravenous; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

Innovations in IV Medications for Life-threatening OTC Deficiency Surface amidst COVID-19 Outbreak

Since OTC deficiency is a rare X-linked genetic disorder, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are under pressure to increase the availability of drugs amidst the COVID-19 (coronavirus) outbreak. Messenger RNA drug developer Arcturus Therapeutics has not only received the FDA’s (Food & Drug Association) approval for clinical trials of ARCT-810, an investigational treatment for OTC deficiency, but is also testing its coronavirus vaccine candidate. Thus, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are tapping revenue opportunities by innovating in COVID-19 vaccines.

OTC deficiency is a life-threatening disorder, which needs extra care and attention during the COVID-19 pandemic. Companies are collaborating with retail and hospital pharmacies to avoid supply shocks for OTC deficiency medications, as most individuals are opting for remote healthcare diagnosis. They are innovating in intravenous (IV) medications since no FDA-approved drugs exist for the disorder.

Request a sample to get extensive insights into the Ornithine Transcarbamylase (OTC) Deficiency Treatment Market

Gene Therapy Helps Minimize Neurological Deficits and Liver Damage in Patients

Gene therapy holds promising potentials in ornithine transcarbamylase (OTC) deficiency treatment. The Boston Children’s Hospital is creating awareness about gene therapy, since OTC deficiency is a genetic condition caused due to the mutation of the OTC gene. By providing a healthy copy of the OTC gene through gene therapy, doctors aim to reduce incidence of neurological deficits and liver damage. Liver transplantation is another solution for ornithine transcarbamylase deficiency treatment.

Companies in the ornithine transcarbamylase (OTC) deficiency treatment market are increasing their production capabilities to manufacture BUPHENYL® (sodium phenylbutyrate) tablets and powder for oral administration. Since urea cycle disorders are commonly associated with the OTC deficiency, manufacturers in the ornithine transcarbamylase (OTC) deficiency treatment market are increasing the availability of BUPHENYL® to minimize adverse events in patients. BUPHENYL® is being used as an adjunctive therapy for chronic management of OTC deficiency.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Safety Information Enables Management of Extremely High Levels of Ammonia in Blood

Ravicti has become the gold standard for the treatment of the OTC deficiency. This oral liquid is being increasingly used for long-term management of high blood levels containing ammonia that commonly lead to urea cycle disorders (UCDs). Healthcare practitioners are recommending low-protein diet and dietary supplements to OTC deficiency patients. However, Ravicti has limitations for the treatment of extremely high levels of ammonia in the blood, especially in patients with UCD. This explains why the market is estimated to register a modest CAGR of ~4% during the forecast period. Hence, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are increasing awareness about the safety of Ravicti to avoid serious side effects in patients.

OTC deficiency patients with kidney and liver problems need to seek doctor’s consultation before consuming Ravicti. Clinicians are providing special care to pregnant women and women who are breastfeeding to avoid any adverse events in infants.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Ornithine Transcarbamylase (OTC) Deficiency Treatment Market

Ammonul IV Holds Promising Potentials for Lowering Ammonia Levels in OTC Deficiency Patients

The FDA prescribed information is being used by medical practitioners to administer the doses of Ammonul in OTC deficiency patients. Genetics and metabolic experts are recommending hemodialysis as an effective solution to reduce plasma ammonia in OTC deficiency patients. As such, Ammonul is being extensively taken via intravenous administration to reduce the severity of UCDs. Ammonul IV helps in removing glycine and glutamate from plasma, thereby reducing contribution to ammonia formation. Thus, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are increasing their R&D capabilities to develop improved formulations of Ammonul IV.

Since the management and diagnosis of UCD is complex, pathologists, nephrologists, and geneticists are stepping in to lower ammonia levels in the blood of OTC deficiency patients.

Nitrogen Scavenger Therapy Ensures Long-term UCD Management

The ornithine transcarbamylase (OTC) deficiency treatment market is projected to reach ~US$ 900 Mn by the end of 2030. However, limited consensus regarding long-term management approaches for OTC deficiency is potentially inhibiting market growth. Hence, pharmaceutical companies are introducing efficacious dietary supplements to keep ammonia levels in the blood under control. On the other hand, nitrogen scavenger therapy is being highly publicized to ensure long-term UCD management and to minimize the nitrogen load.

Companies in the ornithine transcarbamylase (OTC) deficiency treatment market are increasing awareness about a multidisciplinary approach for long-term UCD management. Since the male population is at a higher risk of being susceptible to the OTC deficiency, biochemical geneticists, dieticians and neuropsychologists are collaborating to introduce guidelines associated with chronic ammonia targets.

Dieticians Deliver Complex Calculations for Intake of Protein and Dietary Supplements

It has been found that a dietician’s consultation helps to improve clinical outcomes in OTC deficiency patients. Along with dietary supplements, nutritionists are recommending low-protein diets to improve the quality of life for OTC deficiency individuals. Patients that are adherent to the UCD therapy are also warranted for genetic testing to ensure successful management of OTC deficiency. Dieticians are playing an instrumental role in complex calculations related to the intake of protein and dietary supplements, which depends on different variables such as age-related growth rate, physical activity, and residual urea cycle function.

Providing the right amount of protein is necessary for efficient management of the OTC deficiency. Hence, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are suggesting routine diagnosis of the rare disorder in order to increase clinical numbers. IV and oral drugs are being routinely used for long-term management of UCD in OTC deficiency patients.

Analysts’  Viewpoint

Since UCD associated with OTC deficiency can be potentially life threating for patients amidst the COVID-19 pandemic, companies in the ornithine transcarbamylase (OTC) deficiency treatment market are boosting their production capacities to increase the availability of IV and oral drugs. Gene therapy and nitrogen scavenger therapy are gaining popularity for long-term management of ammonia in blood streams. Since there is a lack of FDA-approved drugs for the OTC deficiency, companies in the ornithine transcarbamylase (OTC) deficiency treatment market should increase their R&D capabilities to innovate in IV medications. Companies should innovate in dietary supplements, since a close check on daily intake of protein and supplements helps to improve patient quality of life.

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market: Overview

  • Ornithine transcarbamylase deficiency, a highly common urea cycle disorder and rare X-linked genetic disorder, is characterized by partial or a complete lack of enzyme ornithine transcarbamylase (OTC)
  • OTC is one of six enzymes that play a role in breakdown and removal of nitrogen in the body, a process known as the urea cycle
  • OTC deficiency is a genetic disorder characterized by a complete or partial lack of the enzyme ornithine transcarbamylase (OTC). It is an abnormal gene on the X chromosome and manifests mostly in males.
  • Both males and females may develop symptoms of OTC deficiency during childhood. Females who have a defective gene present on one of their X chromosomes are carriers for the disorder.

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market: Drivers

  • Rising prevalence of OTC deficiency and development of new therapies for the treatment of OTC deficiency are major factors boosting the global ornithine transcarbamylase (OTC) deficiency treatment market
  • For instance, according to Orphanet, the estimated prevalence of ornithine transcarbamylase deficiency ranges between 1/56,500 and 1/113,000 live births across the world
  • Favorable reimbursement scenario and patient assistance programs provided by various international as well as regional organizations are also major drivers of the global Ornithine Transcarbamylase (OTC) deficiency treatment market
  • Patient compliance is affected due to bitter taste and foul odor of products. Hence, research and development is being carried out to develop new formulations of this drug in order to overcome such serious issues.
  • Consequently, formulation modification for better patient compliance also propels the global ornithine transcarbamylase (OTC) deficiency treatment market

Market Segmentation: Ornithine Transcarbamylase (OTC) Deficiency Treatment Market

  • In terms of product, the global ornithine transcarbamylase (OTC) deficiency treatment market has been divided into Buphenyl, Ravicti, Ammonul, dietary supplements, and others
  • Based on route of administration, the global ornithine transcarbamylase (OTC) deficiency treatment market has been bifurcated into oral and intravenous
  • In terms of distribution channel, the global ornithine transcarbamylase (OTC) deficiency treatment market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies
  • Each of the ornithine transcarbamylase (OTC) deficiency treatment market segments has been analyzed in detail for market trends, recent trends and developments, drivers, restraints, opportunities, and useful insights
  • The ornithine transcarbamylase (OTC) deficiency treatment market report provides current and future revenues (US$ Mn) for each of the segments for the period from 2018 to 2030, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2020 to 2030 along with market size estimations.

Regional Overview: Ornithine Transcarbamylase (OTC) Deficiency Treatment Market

  • In terms of region, the global ornithine transcarbamylase (OTC) deficiency treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • North America dominated the global ornithine transcarbamylase (OTC) deficiency treatment market in 2019, and the trend is projected to continue during the forecast period
  • The current and future sizes of the ornithine transcarbamylase (OTC) deficiency treatment market, in terms of value (US$ Mn), of regional markets and their major countries have been provided in the report for the period from 2018 to 2030, along with their CAGRs for the period from 2020 to 2030
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which would help new companies willing to enter the market and existing companies to increase market shares and help in the decision-making process

Major Players

  • The ornithine transcarbamylase (OTC) deficiency treatment market report concludes with the company profiles section that includes key information about the major players in the market
  • Key players analyzed in the ornithine transcarbamylase (OTC) deficiency treatment market report are -
    • Abbott
    • Nutricia (Danone Group)
    • Mead Johnson (Reckitt Benckiser)
    • Horizon Therapeutics plc
    • Nestlé
    • Bausch Health Companies, Inc.
    • Ultragenyx Pharmaceutical Inc.
    • Arcturus Therapeutics, Inc.
    • Acer Therapeutics
  • Each of these players has been profiled in the global ornithine transcarbamylase (OTC) deficiency treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market – Segmentation 

TMR’s study on the global ornithine transcarbamylase (OTC) deficiency treatment market includes information divided into four sections: product, route of administration, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these sections of the global ornithine transcarbamylase (OTC) deficiency treatment market have been discussed in detail.

Product

  • Buphenyl
  • Ravicti
  • Ammonul
  • Dietary Supplements
  • Others

Route of Administration

  • Oral
  • Intravenous

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Ornithine Transcarbamylase (OTC) Deficiency Treatment Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of ornithine transcarbamylase (OTC) deficiency treatment market?

Ornithine transcarbamylase (OTC) deficiency treatment market is projected to reach ~US$ 900 Mn by 2030

What is the anticipated CAGR of the ornithine transcarbamylase (OTC) deficiency treatment market in the forecast period?

Ornithine transcarbamylase (OTC) deficiency treatment market is projected to expand at a CAGR of ~4% from 2020 to 2030

What are the key driving factors for the growth of the ornithine transcarbamylase (OTC) deficiency treatment market?

Ornithine transcarbamylase (OTC) deficiency treatment market is driven by rising prevalence of OTC deficiency and development of new therapies for the treatment of OTC deficiency

Which region is expected to project the highest market share in the global ornithine transcarbamylase (OTC) deficiency treatment market?

North America accounted for a major share of the global ornithine transcarbamylase (OTC) deficiency treatment market

Who are the key players in the global ornithine transcarbamylase (OTC) deficiency treatment market?

Key players in the global ornithine transcarbamylase (OTC) deficiency treatment market include Abbott, Nutricia (Danone Group), Mead Johnson (Reckitt Benckiser), Horizon Therapeutics plc, Nestlé, Bausch Health Companies

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, 2018–2030

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Disease Prevalence & Incidence Rate globally with key countries

    5.2. Pipeline Analysis

    5.3. Standard Guidelines for Approval of Drugs

    5.4. Overview of Diagnostics approach for OTC Deficiency

    5.5. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Product 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030

        6.3.1. Buphenyl

        6.3.2. Ravicti

        6.3.3. Ammonul

        6.3.4. Dietary Supplements

        6.3.5. Others

    6.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product 

7. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Route of Administration 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030

        7.3.1. Oral

        7.3.2. Intravenous

    7.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration 

8. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Distribution Channel 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel 

9. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Region

10. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030

        10.2.1. Buphenyl

        10.2.2. Ravicti

        10.2.3. Ammonul

        10.2.4. Dietary Supplements

        10.2.5. Others

    10.3. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030

        10.3.1. Oral

        10.3.2. Intravenous

    10.4. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country, 2018–2030

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis 

        10.6.1. By Product 

        10.6.2. By Route of Administration 

        10.6.3. By Distribution Channel 

        10.6.4. By Country

11. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030

        11.2.1. Buphenyl

        11.2.2. Ravicti

        11.2.3. Ammonul

        11.2.4. Dietary Supplements

        11.2.5. Others

    11.3. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030

        11.3.1. Oral

        11.3.2. Intravenous

    11.4. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis 

        11.6.1. By Product 

        11.6.2. By Route of Administration 

        11.6.3. By Distribution Channel 

        11.6.4. By Country/Sub-region

12. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030

        12.2.1. Buphenyl

        12.2.2. Ravicti

        12.2.3. Ammonul

        12.2.4. Dietary Supplements

        12.2.5. Others

    12.3. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030

        12.3.1. Oral

        12.3.2. Intravenous

    12.4. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis 

        12.6.1. By Product 

        12.6.2. By Route of Administration 

        12.6.3. By Distribution Channel 

        12.6.4. By Country/Sub-region

13. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030

        13.2.1. Buphenyl

        13.2.2. Ravicti

        13.2.3. Ammonul

        13.2.4. Dietary Supplements

        13.2.5. Others

    13.3. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030

        13.3.1. Oral

        13.3.2. Intravenous

    13.4. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis 

        13.6.1. By Product 

        13.6.2. By Route of Administration 

        13.6.3. By Distribution Channel 

        13.6.4. By Country/Sub-region

14. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Product, 2018–2030

        14.2.1. Buphenyl

        14.2.2. Ravicti

        14.2.3. Ammonul

        14.2.4. Dietary Supplements

        14.2.5. Others

    14.3. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Route of Administration, 2018–2030

        14.3.1. Oral

        14.3.2. Intravenous

    14.4. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Distribution Channel, 2018–2030

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Forecast, by Country/Sub-region, 2018–2030

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis 

        14.6.1. By Product 

        14.6.2. By Route of Administration 

        14.6.3. By Distribution Channel 

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player – Competition Matrix (By Tier and Size of companies)

    15.2. Market Share/Position Analysis, by Company (2019)

    15.3. Company Profiles

        15.3.1. Abbott

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Company Financials

            15.3.1.3. Growth Strategies

            15.3.1.4. SWOT Analysis

        15.3.2. Nutricia (Danone Group)

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Company Financials

            15.3.2.3. Growth Strategies

            15.3.2.4. SWOT Analysis

        15.3.3. Mead Johnson (Reckitt Benckiser)

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Company Financials

            15.3.3.3. Growth Strategies

            15.3.3.4. SWOT Analysis

        15.3.4. Horizon Therapeutics plc

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Company Financials

            15.3.4.3. Growth Strategies

            15.3.4.4. SWOT Analysis

        15.3.5. Nestlé

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Company Financials

            15.3.5.3. Growth Strategies

            15.3.5.4. SWOT Analysis

        15.3.6. Bausch Health Companies, Inc.

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Company Financials

            15.3.6.3. Growth Strategies

            15.3.6.4. SWOT Analysis

        15.3.7. Ultragenyx Pharmaceutical Inc.

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Company Financials

            15.3.7.3. Growth Strategies

            15.3.7.4. SWOT Analysis

        15.3.8. Arcturus Therapeutics, Inc.

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Company Financials

            15.3.8.3. Growth Strategies

            15.3.8.4. SWOT Analysis

        15.3.9. Acer Therapeutics

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Company Financials

            15.3.9.3. Growth Strategies

            15.3.9.4. SWOT Analysis

List of Tables

Table 01: Pipeline Analysis

Table 02: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 03: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 04: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 05: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 06: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 07: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 08: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 09: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 10: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 11: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 12: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 13: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 14: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 15: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 16: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 17: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 18: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 19: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 20: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 21: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 22: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 23: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 24: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 25: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

List of Figures

Figure 01: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast, 2018–2030

Figure 02: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share, by Product, 2019

Figure 03: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share, by Route of Administration, 2019

Figure 04: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share, by Distribution Channel, 2019

Figure 05: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share, by Region, 2019

Figure 06: Regulatory Approval Process - U.S.

Figure 07: Regulatory Approval Process - Europe 

Figure 08: Regulatory Approval Process - Japan

Figure 09: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share Analysis, by Product, 2019 and 2030

Figure 10: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Buphenyl, 2018–2030

Figure 11: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Ravicti, 2018–2030

Figure 12: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Ammonul, 2018–2030

Figure 13: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Dietary Supplements, 2018–2030

Figure 14: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Others, 2018–2030

Figure 15: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis, by Product, 2020–2030

Figure 16: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 17: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Oral, 2018–2030

Figure 18: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Intravenous, 2018–2030

Figure 19: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 20: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 21: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2018-2030

Figure 22: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2018-2030

Figure 23: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn), by Online Pharmacies, 2018–2030

Figure 24: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 25: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share Analysis, by Region, 2019 and 2030

Figure 26: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness Analysis, by Region, 2020–2030

Figure 27: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 28: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Country, 2019 and 2030

Figure 29: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country, 2020–2030

Figure 30: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Product, 2019 and 2030

Figure 31: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product, 2020–2030

Figure 32: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 33: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 34: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 35: North America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 36: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 37: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 38: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

Figure 39: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Product, 2019 and 2030

Figure 40: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product, 2020–2030

Figure 41: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 42: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 43: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 44: Europe Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 45: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 46: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 47: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

Figure 48: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Product, 2019 and 2030

Figure 49: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product, 2020–2030

Figure 50: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 51: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 52: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 53: Asia Pacific Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 54: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 55: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 56: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

Figure 57: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Product, 2019 and 2030

Figure 58: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product, 2020–2030

Figure 59: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 60: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 61: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 62: Latin America Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 63: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 64: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 65: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

Figure 66: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Product, 2019 and 2030

Figure 67: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Product, 2020–2030

Figure 68: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 69: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 70: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 71: Middle East & Africa Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 72: Market Position Analysis, 2019, by Tier and Size of Company

Figure 73: Abbott, Nutritional Business Segment - Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019

Figure 74: Abbott, Nutritional Business Segment - Breakdown of Net Sales (%), by Region/Country, 2019

Figure 75: Abbott, Breakdown of Net Sales (%), by Nutritional Business Segment, 2019

Figure 76: Abbott, R&D Expenses (US$ Mn) Y-o-Y Growth (%), 2016–2019

Figure 77: Danone - Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019

Figure 78: Danone - Breakdown of Net Sales (%), by Region/Country, 2019

Figure 79: Danone - Breakdown of Net Sales (%), by Business Segment, 2019

Figure 80: Reckitt Benckiser - Revenue (US$ Mn), 2016–2018

Figure 81: Reckitt Benckiser - Breakdown of Net Sales (%), by Region/Country, 2018

Figure 82: Reckitt Benckiser - Breakdown of Net Sales (%), by Business Segment, 2018

Figure 83: Horizon Therapeutics plc - Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019

Figure 84: Horizon Therapeutics plc - Breakdown of Net Sales (%), by Region/County, 2019

Figure 85: Horizon Therapeutics plc - Breakdown of Net Sales (%), by Business Segment, 2019

Figure 86: RAVICTI & BUPHENYL - Product Revenue (US$ Mn), 2017–2019

Figure 87: Nestlé - Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 88: Nestlé - Breakdown of Net Sales (%), by Region/County, 2019

Figure 89: Nestlé - Breakdown of Net Sales (%), by Product Line, 2019

Figure 90: Bausch Health Companies, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 91: Bausch Health Companies, Inc., Breakdown of Net Sales (%), by Region/County, 2019

Figure 92: Bausch Health Companies, Inc., Breakdown of Net Sales (%), by Business Segment, 2019

Figure 93: Bausch Health Companies, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2019

Figure 94: Ultragenyx Pharmaceutical, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019

Figure 95: Ultragenyx Pharmaceutical, Inc., Breakdown of Net Sales (%), by Region/County, 2019

Figure 96: Ultragenyx Pharmaceutical, Inc., DTX301 - R&D Expenses (US$ Mn) Y-o-Y Growth (%), 2018–2019

Figure 97: Ultragenyx Pharmaceutical, Inc., R&D Expenses (US$ Mn) Y-o-Y Growth (%), 2016–2019

 Figure 98: Arcturus Therapeutics, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 99: Arcturus Therapeutics, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

924

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved